How automation can help biotech startups

The 21^st century is quickly emerging as the Century of Biology, with discoveries happening at a rate that was previously unthinkable. Cutting-edge discoveries in this field have paved the way for real-world applications in fields from environmental conservation to personalized medicine.

This revolution was sparked by technologies like CRISPR-Cas9 and next-generation sequencing, but the integration of artificial intelligence and a variety of high throughput techniques is expected to accelerate development.

Scientists from both small and large firms are racing to use new scientific discoveries. With this pressure set to increase, successful innovators looking to make a real impact will need more than just a great idea; they will also need to embrace new technologies early on to develop and bring their vision to market effectively.

Image Credit: PopTika / Shutterstock.com

A company can improve its trajectory by carefully addressing future needs: forward-thinking technology adoption early in its life cycle could pave the way to sustained funding and, eventually, commercialization ahead of competition.

For early-stage biotech companies, securing the next round of funding is not just a milestone; it often serves as a gateway to a new phase of research or growth. Each round of funding marks the beginning of a new countdown, accompanied by a fresh set of objectives. While this might seem like a race, the truth is that quality and the capacity to showcase readiness for the next phase are just as crucial as hitting predefined milestones.

Therefore, companies must not only move quickly before funding runs out or a competitor outpaces them but must do so in a credible and reproducible way to ensure investors have the confidence to finance their future growth.

Summary

Biotechnology startups encounter unique and difficult challenges throughout their existence. While it may seem that generating scientific outcomes within tight deadlines is paramount for survival, seasoned entrepreneurs understand that this simplistic view can be misleading. Meeting milestones alone does not guarantee additional funding, often leaving companies puzzled and uncertain about their future.

As investors are faced with a seemingly endless menu of companies, it becomes essential for those companies to proactively demonstrate that they are more than their recent scientific results. By demonstrating not only speed but scientific rigor, efficiency, and preparedness for the future, startup companies can distinguish themselves from the crowd, positioning themselves for success.